Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Tempest Therapeutics stock

Learn how to easily invest in Tempest Therapeutics stock.

Tempest Therapeutics Inc
-$0.35 (-2.72%)

Tempest Therapeutics Inc is a biotechnology business based in the US. Tempest Therapeutics shares (TPST) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Tempest Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TPST – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Tempest Therapeutics stock price (NASDAQ: TPST)

Use our graph to track the performance of TPST stocks over time.

Tempest Therapeutics shares at a glance

Information last updated 2021-08-01.
52-week range$10.39 - $41.55
50-day moving average $17.10
200-day moving average $22.81
Wall St. target price$23.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Tempest Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Tempest Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tempest Therapeutics financials

Gross profit TTM $0
Return on assets TTM -79.27%
Return on equity TTM -196.78%
Profit margin 0%
Book value N/A
Market capitalisation $99.7 million

TTM: trailing 12 months

Shorting Tempest Therapeutics shares

There are currently 277,728 Tempest Therapeutics shares held short by investors – that's known as Tempest Therapeutics's "short interest". This figure is 57.6% up from 176,216 last month.

There are a few different ways that this level of interest in shorting Tempest Therapeutics shares can be evaluated.

Tempest Therapeutics's "short interest ratio" (SIR)

Tempest Therapeutics's "short interest ratio" (SIR) is the quantity of Tempest Therapeutics shares currently shorted divided by the average quantity of Tempest Therapeutics shares traded daily (recently around 2.5 million). Tempest Therapeutics's SIR currently stands at 0.11. In other words for every 100,000 Tempest Therapeutics shares traded daily on the market, roughly 110 shares are currently held short.

However Tempest Therapeutics's short interest can also be evaluated against the total number of Tempest Therapeutics shares, or, against the total number of tradable Tempest Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tempest Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Tempest Therapeutics shares in existence, roughly 40 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Tempest Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tempest Therapeutics.

Find out more about how you can short Tempest Therapeutics stock.

Tempest Therapeutics share dividends

We're not expecting Tempest Therapeutics to pay a dividend over the next 12 months.

Have Tempest Therapeutics's shares ever split?

Tempest Therapeutics's shares were split on a 1:15 basis on 27 June 2021. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tempest Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Tempest Therapeutics shares which in turn could have impacted Tempest Therapeutics's share price.

Tempest Therapeutics overview

Tempest Therapeutics Inc. , a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa. Its TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study agents as monotherapies and in combination with other approved agents. The company is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. The company is headquartered in South San Francisco, California. Tempest Therapeutics Inc.

Frequently asked questions

What percentage of Tempest Therapeutics is owned by insiders or institutions?
Currently 1.313% of Tempest Therapeutics shares are held by insiders and 21.773% by institutions.
Where is Tempest Therapeutics based?
Tempest Therapeutics's address is: 7000 Shoreline Court, South San Francisco, CA, United States, 94080

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site